|Table of Contents|

Clinical characteristics and prognostic factors of 51 patients with mantle cell lymphoma in western China

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
630-635
Research Field:
Publishing date:

Info

Title:
Clinical characteristics and prognostic factors of 51 patients with mantle cell lymphoma in western China
Author(s):
Duan Xiaohui; Wang Jianhong; Hao Caixia; Zheng Yanhua; Zhang Tao; Gu Hongtao; Bai Qingxian; Yang Lan; Dong Baoxia; Tang Hailong; Gao Guangxun; Liang Rong
Department of Hematology，Xijing Hospital of Air Force Medical University,Shaanxi Xi'an 710032,China.
Keywords:
mantle cell lymphoma; clinical features; prognostic factors
PACS:
R733.41
DOI:
10.3969/j.issn.1672-4992.2020.04.025
Abstract:
Objective：To study the clinical characteristics and prognostic factors of patients with mantle cell lymphoma（MCL) for comprehensive assessment of the condition and exploring individualized treatment.Methods:The clinical characteristics of 51 MCL patients from the department of hematology of our hospital from January 2012 to December 2016 were analyzed retrospectively.The prognostic stratification,short-term and long-term effects of different chemotherapy regimens were also analyzed retrospectively in 20 inpatients．Results:The ORR of R-Hyper-CVAD group（100%) and R-CHOP like group（100%) were higher than those groups without rituximab （50%,40%).In the MIPI score,the ORR of the low risk group was 75.0%,which was significantly higher than that of the moderate risk group（16.6%).The CR and PR of CD5- patients was higher than that of CD5+ patients.The CR of patients with Ki67≥30%（20%) was higher than that of patients with Ki67<30%（11%).But the tendency of PR was opposite to that of CR.The 3 years OS in Ki67<30% group was significantly higher than that in patients with Ki67≥30%.But there was no significant difference in PFS in these two crowd.In MIPI group,3 years OS in low risk group was significantly higher than that in intermediate and high risk group.However,there was no significant difference in PFS.Both OS and PFS were higher in the rituximabplus chemotherapy group than that of chemotherapy alone group.There was no statistical difference in PFS and OS between Hyper-CVAD group and non-Hyper-CVAD group.Conclusion:The efficacy of combined chemotherapy with rituximab in the treatment of MCL is definite.The vast majority of patients can toleratelow intensity of Hyper-CVAD A or B chemotherapy.However,there was no statistical difference between the Hyper-CVAD group and the non-Hyper-CVAD group.This may be attributed to the low sample size.Further study of more large samples of evidence-based medicine is needed.

References:

[1] Swerdlow SH,Campo E,Harris NL，et al.World Health Organization classification of tutours of heamatopoietic and lymphoid tissue［M］．4th ed.Lyon:IARC Press，2008：194-195.
[2] DU JW,WEI XD.Analysis of treatment status of non-Hodgkin lymphoma［J］.Clinical Meta，2015,30（10）：1110-1119.［杜建伟，魏旭东.非霍奇金淋巴瘤治疗现状分析［J］.临床荟萃，2015,30（10）：1110-1119.］
[3] Hoster E，Dreyling M，Klapper W，et al． A new prognostic index（MIPI） for patients with advanced-stage mantle cell lymphoma［J］．Blood，2008,111(2):558-565．
[4]Sgkorová A，Pytlík R，Móciková H， et al． Staging and treatment response evaluation in malignant lymphomasczech lymphoma study group recommendations［J］．Klin Onkol，2016， 29（4):295-302．
[5]LIANG R,WANG Z,ZHU MN,et al.Clinical features and prognostic factors of 23 patients with mantle cell lymphoma［J］.Chinese Blood Journal,2016,37（6）:491-496.［梁蓉，王哲，朱米娜,等.23例套细胞淋巴瘤患者临床特征及预后相关因素分析［J］.中华血液杂志，2016,37（6）:491-496.］
[6]Martin P,Chadburn A,Christos P,et al.Outcome of deferred initial therapy in mantle-cell lymphoma［J］．J Clin Oncol,2009(27):1209-1213.
[7]CHEN SP，WU WQ,SHEN HW,et al.Expression of IgH/CCND1 fusion gene and cell cycle associated protein in mantle cell lymphoma［J］.Journal of Clinical and Experimental Pathology,2017,33（5）:511-514.［陈顺平，吴文乔，沈洪武,等.套细胞淋巴瘤中IgH/CCND1 融合基因及细胞周期相关蛋白的表达［J］.临床与实验病理学杂志，2017,33（5）:511-514.］
[8]Fernandez V,Salamero O,Espinet B,et al.Genomic and gene expression profiling defines indolent forms of mantle-cell lymphoma［J］．Cancer Res，2010(70):1408-1418.
[9]Nordstrom L,Sernbo S,Eden P,et al.SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma-a Nordic Lymphoma Group study［J］.Bri J Haematol,2014(166):98-108.
[10]Geisler CH,Kolstad A,Laurell A,et al.The mantle cell lymphoma international prognostic index(MIPI) is superior to the international prognostic index(IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation(ASCT)［J］.Blood,2010(115):1530-1533.
[11]Obr A，Vít P，Andrea J，et al.TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma［J］.Clin Lymphoma Myeloma Leuk,2018.https://doi.org/10.1016/j.clml.2018.07.282.
[12]Xu J,Medeiros LJ，Saksena A，et al.CD10-positive mantle cell lymphoma:Clinicopathologic and prognostic study of 30 cases［J］.Oncotarget,2018(9):11441-11450.
[13]XIE Y,ZHU J.Consensus of Chinese experts on diagnosis and treatment of mantle cell lymphoma(Version 2016)［J］.J Clin Hematol,2017,30（9）:683-685.［谢彦，朱军.套细胞淋巴瘤诊断与治疗中国专家共识（2016版）解读［J］.临床血液学杂志，2017,30（9）:683-685.］
[14]ZHU MN，DUAN XH，LIANG R,et al.Clinical analysis of 16 cases of mantle cell lymphoma［J］.J Clin Hematol，2014，27（7）：593-596.［朱米娜，段晓晖，梁蓉,等.16例套细胞淋巴瘤临床病例分析［J］.临床血液学杂志，2014，27（7）：593-596.］
[15]Vidal L,Gafter-Gvili A,Dreyling M，et al.Rituximab maintenance(MR) for patients with mantle cell lymphoma（MCL）-A systemic review and meta-analysis of the randomized controlled trials(RCTS)［J］.Blood,2016(128):1802.
[16]Obr A,Prochazka V，Papajik T，et al.Maintenance rituximab in newly diagnosed mantle cell lymphoma patients:A real world analysis from the Czech lymphoma study groupregistry［J］.Leuk Lymphoma,2018.doi:10.1080/10428194.2018.1508672.
[17]Zinzani PL,Pellegrini C,Merla E,et al.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients:A multicenter retrospective study ［J］.Hematol Oncoll,2013(31):179-182.
[18]FAN WJ，WU T,BAI H,et al.Advances in research and application of lenalidomide in mantle cell lymphoma［J］.J Clin Hematol,2018,31（1）:77-80.［樊文静，吴涛，白海，等.来那度胺在套细胞淋巴瘤中的研究及应用进展［J］.临床血液学杂志，2018,31（1）:77-80.］

Memo

Memo:
National Natural Science Foundation of China（No.81370641）;国家自然科学基金（编号：81370641）
Last Update: 2019-12-26